Shareholder approval removes a key condition for the Angelini Pharma acquisition. The stock should trade near the $31.50 offer price as regulatory approvals are pursued. Monitor for closing timeline and any regulatory hurdles.
Price Chart
Executive Summary
Catalyst Pharmaceuticals stockholders approved the $31.50/share all-cash acquisition by Angelini Pharma at the July 8, 2026 special meeting, with over 79% of outstanding shares voting in favor. The compensation proposal for executives was rejected on a non-binding advisory basis, but this does not affect deal closure. All directors have indicated their intent to resign effective at merger closing. The merger now has cleared its key stockholder condition.
Key Facts
- Merger proposal approved by holders of 97,340,180 shares For (79.5% of outstanding) vs. 1,143,815 Against and 242,616 Abstentions.
- Advisory compensation proposal NOT approved (30,504,686 For, 67,486,884 Against) but non-binding and not a condition to closing.
- All seven directors intend to resign effective at merger closing; no disagreements cited.
- 80.6% of outstanding shares were present or represented at the special meeting.
Financial Impact
All-cash acquisition at $31.50/share; total deal value not disclosed in this filing but implied by market cap of $3.9B.
Risk Factors
- Regulatory approvals or antitrust clearance may delay or block the merger.
- Shareholder lawsuit related to proxy disclosures remains outstanding (per prior DEFA14A).
- Merger termination rights under the agreement if closing conditions not met by outside date.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (CPRX) — Batch item 1 | 0001193125-26-298739 |
| Document: 0001193125-26-298739-index-headers.html | 0001193125-26-298739 |
| Document: 0001193125-26-298739-index.html | 0001193125-26-298739 |
| Document: 0001193125-26-298739.txt | 0001193125-26-298739 |
| 8-K Filing (CPRX) — Batch item 5 | 0001193125-26-298739 |
| Document: 0001193125-26-298739-index-headers.html | 0001193125-26-298739 |
| Document: 0001193125-26-298739-index.html | 0001193125-26-298739 |
| Document: 0001193125-26-298739.txt | 0001193125-26-298739 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 22, 2026 5w ago | Institutional Cluster | — | awaiting T+5 | — | — |
Jul 24, 2026 9w ago | 15-12G | $31.49 awaiting T+5 | awaiting T+5 | — | — |
Jul 17, 2026 11w ago | EFFECT | $31.49 $31.49 | · 0.00% | ▼ −0.59% | — |
Jul 15, 2026 11w ago | 25-NSE | $31.49 $31.49 | · 0.00% | ▼ −0.98% | — |
Jul 8, 2026 12w ago | 8-K | $31.47 $31.49 | ▲ +0.06% | ▲ +0.20% | — |
Jun 30, 2026 13w ago | DEFA14A | $31.44 $31.49 | ▲ +0.16% | ▼ −0.10% | — |
Jun 30, 2026 13w ago | 8-K | $31.44 $31.49 | ▲ +0.16% | ▼ −0.10% | — |
May 28, 2026 18w ago | PREM14A | $31.23 $31.28 | ▲ +0.16% | ▲ +0.45% | — |
May 12, 2026 20w ago | DEFA14A | $31.14 $31.23 | ▲ +0.29% | ▲ +0.21% | — |
May 11, 2026 20w ago | Press Release | $31.14 $31.23 | ▼ −0.29% | ▼ −0.21% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access